INAB
IN8bio, Inc. NASDAQ Listed Jul 30, 2021$1.42
+0.71%
vs $1.41
Mkt Cap $6.2M
52w Low $1.21
15.2% of range
52w High $2.59
50d MA $1.53
200d MA $1.80
P/E (TTM)
-0.4x
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.1x
ROE
-70.5%
P/FCF
-0.5x
RSI (14)
52.00
ATR (14)
$0.07
Beta
0.04
50d MA
$1.53
200d MA
$1.80
Avg Volume
55.8K
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
CIK (SEC)
Phone
646 600 6438
350 5th Avenue · New York City, NY 10118 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.18 | -0.26 | -44.4% | 1.91 | -0.5% | -1.0% | +9.0% | -7.3% | -3.7% | -6.5% | — |
| Nov 6, 2025 | AMC | -1.20 | -0.85 | +29.2% | 1.66 | -3.6% | -6.6% | +11.0% | -2.3% | +1.2% | -3.5% | — |
| Aug 7, 2025 | AMC | -1.50 | -1.24 | +17.3% | 2.15 | +0.0% | +7.4% | -1.7% | -0.9% | +1.8% | +4.8% | — |
| May 7, 2025 | AMC | -1.80 | -2.10 | -16.7% | 4.93 | +2.2% | +2.2% | -6.3% | +3.6% | -1.8% | -8.3% | — |
| Mar 13, 2025 | AMC | -0.07 | -0.04 | +42.9% | 6.79 | +1.6% | -0.4% | +0.4% | +1.0% | +3.2% | -1.3% | — |
| Nov 12, 2024 | AMC | -0.14 | -0.15 | -7.1% | 10.50 | -14.0% | -9.5% | +6.1% | -0.2% | -1.1% | -4.4% | — |
| Aug 8, 2024 | AMC | -0.16 | -0.19 | -18.8% | 20.52 | +2.3% | +2.2% | -9.2% | +2.2% | -7.5% | +0.5% | — |
| May 9, 2024 | AMC | -0.17 | -0.20 | -17.6% | 30.30 | -1.7% | +0.0% | +1.0% | +2.0% | +8.7% | -9.7% | — |
| Mar 14, 2024 | AMC | -0.16 | -0.21 | -31.2% | 34.80 | +1.7% | -1.7% | +7.9% | -2.4% | +6.7% | -2.3% | — |
| Nov 9, 2023 | AMC | -0.25 | -0.23 | +8.0% | 30.30 | -0.1% | +3.0% | +1.0% | -5.7% | -5.1% | -2.0% | — |
| Aug 10, 2023 | AMC | -0.28 | -0.27 | +3.6% | 34.50 | +2.6% | +1.7% | +0.0% | +1.7% | -0.8% | -3.4% | — |
| May 12, 2023 | AMC | -0.33 | -0.30 | +9.1% | 70.50 | -0.4% | +4.7% | +8.5% | +4.1% | +13.3% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.91 | $1.90 | -0.5% | -1.0% | +9.0% | -7.3% | -3.7% | -6.5% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.79 | $6.90 | +1.6% | -0.4% | +0.4% | +1.0% | +3.2% | -1.3% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.20 | $8.43 | -8.4% | -5.1% | +11.0% | -10.0% | -8.1% | +10.2% |
| Feb 11 | Jones Trading | Upgrade | Hold → Buy | — | $8.10 | $11.96 | +47.7% | +13.6% | -5.1% | +11.0% | -10.0% | -8.1% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.11 | $9.45 | +3.7% | +2.1% | -4.4% | +2.8% | +20.8% | -13.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.50 | $9.03 | -14.0% | -9.5% | +6.1% | -0.2% | -1.1% | -4.4% |
| Aug 12 | Jones Trading | Downgrade | Buy → Hold | — | $20.97 | $20.70 | -1.3% | -9.2% | +2.2% | -7.6% | +0.5% | +16.1% |
| Jun 14 | Jones Trading | Maintains | Buy → Buy | — | $50.40 | $45.00 | -10.7% | -35.1% | -8.3% | +0.0% | -8.0% | -3.4% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.40 | $45.00 | -10.7% | -35.1% | -8.3% | +0.0% | -8.0% | -3.4% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.70 | $32.40 | -0.9% | +12.8% | +11.4% | -17.5% | +18.6% | -2.2% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.30 | $30.90 | +2.0% | +1.0% | +2.0% | +8.7% | -9.7% | +1.0% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.70 | $34.80 | +6.4% | +0.9% | +4.5% | -3.5% | -8.1% | -3.9% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.80 | $35.40 | +1.7% | -1.7% | +7.9% | -2.4% | +6.7% | -2.3% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.20 | $32.10 | +2.9% | +1.0% | -5.7% | -5.1% | -2.0% | -1.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.50 | $35.40 | +2.6% | +1.7% | +0.0% | +1.7% | -0.8% | -3.4% |
| Jun 5 | EF Hutton | Maintains | Buy → Buy | — | $94.50 | $91.50 | -3.2% | -13.3% | -7.3% | +1.2% | -5.9% | -11.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.80 | $73.80 | +0.0% | +8.5% | +4.1% | +13.3% | +2.9% | -16.0% |
| Apr 17 | EF Hutton | Maintains | Buy → Buy | — | $36.30 | $38.40 | +5.8% | +6.6% | -1.6% | -9.4% | -2.6% | -6.2% |
| Nov 11 | B. Riley Securities | Downgrade | Buy → Neutral | — | $49.50 | $52.50 | +6.1% | +3.6% | -12.3% | +5.3% | -3.2% | -2.0% |
| Jan 24 | B. Riley Securities | Maintains | Buy → Buy | — | $96.30 | $92.40 | -4.0% | +2.8% | +0.0% | -3.3% | -4.1% | -2.0% |
No insider trades available.
8-K
IN8bio, Inc. -- 8-K Filing
IN8bio has established an at-the-market (ATM) offering program allowing it to sell common stock opportunistically through an agent without obligation to do so.
Jun 1
8-K
Unknown — 8-K Filing
IN8bio's gamma-delta T cell therapy progress and expanding pipeline suggest potential near-term clinical catalysts, though investors should monitor development timelines and competitive positioning in the crowded cell therapy space.
Mar 12
8-K
IN8bio, Inc. -- 8-K Filing
IN8bio's 8-K filing indicates a routine regulatory submission regarding emerging growth company status disclosure requirements under SEC Exchange Act rules.
Feb 27
8-K
IN8bio, Inc. -- 8-K Filing
IN8bio reported compliance filings related to Exchange Act requirements, though the specific material developments affecting investor positions are not detailed in this administrative disclosure.
Feb 9
Institutional (13F) — Top 13
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.p. | 944,319 | $1M | Reduced | Mar 2026 |
| 2 | Franklin Resources Inc | 914,531 | $1M | — | Mar 2026 |
| 3 | Stonepine Capital Management, Llc | 663,412 | $982K | Added | Mar 2026 |
| 4 | Bios Capital Management, Lp | 253,417 | $593K | New | Dec 2025 |
| 5 | Vanguard Capital Management Llc | 88,865 | $132K | New | Mar 2026 |
| 6 | Vanguard Fiduciary Trust Co | 43,570 | $65K | New | Mar 2026 |
| 7 | Captrust Financial Advisors | 33,295 | $49K | Added | Mar 2026 |
| 8 | Oppenheimer & Co Inc | 24,033 | $36K | New | Mar 2026 |
| 9 | Northern Trust Corp | 20,440 | $30K | Added | Mar 2026 |
| 10 | Northwestern Mutual Wealth Management Co | 2,785 | $7K | Reduced | Dec 2025 |
| 11 | Ubs Group Ag | 480 | $710 | Reduced | Mar 2026 |
| 12 | Morgan Stanley | 68 | $160 | New | Dec 2025 |
| 13 | Rockefeller Capital Management L.p. | 83 | $123 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Franklin Biotechnology Discovery Fund | 332,083 | $654K | Jan 2026 |
| 2 | Fidelity Extended Market Index Fund | 16,903 | $29K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 2,595 | $4K | Feb 2026 |
| 4 | Fidelity Total Market Index Fund | 2,040 | $4K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 567 | $975 | Feb 2026 |
Valuation
Market Cap
$6.2M
Enterprise Value
-$19.3M
P/E (TTM)
-0.38x
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.23x
P/S
—
P/FCF
-0.49x
EV/EBITDA
—
Shares Out
4.4M
Financials (TTM)
Revenue
$0
Net Income
-$19.0M
EBITDA
-$16.8M
Free Cash Flow
-$12.7M
Op Cash Flow
-$12.7M
EPS Basic
$-4.44
EPS Diluted
$-3.76
EPS Forward
$-2.09
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$32.3M
Total Liab.
$4.7M
Total Equity
$27.6M
Cash
$27.1M
LT Debt
$1.6M
Book Value/Sh
$6.30
Debt/Equity
0.10x
Current Ratio
8.82
Quick Ratio
8.82
Returns & Growth
ROE
-70.5%
ROA
-60.2%
ROIC
-65.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
-679.0%
Price Returns
2W
+1.4%
1M
-18.5%
3M
+0.7%
6M
-42.7%
12M
-31.9%
Technicals
52W High
$2.59
52W Low
$1.21
50d MA
$1.53
200d MA
$1.80
RSI (14)
52.00
ATR (14)
$0.07
Beta
0.04
Avg Volume
56K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.00
High
$4.00
Low
$4.00
Median
$4.00
Data updated apr 25, 2026 3:26pm
· Source: financialmodelingprep.com